THE EFFECT OF LACTULOSE AND LACTITOL ADMINISTRATION ON FECAL FAT EXCRETION IN PATIENTS WITH LIVER-CIRRHOSIS

被引:18
|
作者
MERLI, M
CASCHERA, M
PIAT, C
PINTO, G
DIOFEBI, M
RIGGIO, O
机构
[1] IInd Cattedra di Gastroenterologia, Università “La Sapienza” di Roma, Rome
关键词
CIRRHOSIS; LACTITOL; LACTULOSE; STEATORRHEA;
D O I
10.1097/00004836-199209000-00009
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Mild to moderate fat malabsorption is frequently present in patients with liver cirrhosis. We investigated the influence of lactulose or lactitol treatment on fecal fat excretion in 18 patients with liver cirrhosis. All patients were Child Pugh class A or B and had not taken any therapy that could have affected intestinal absorption in the previous months. The dose of lactulose or lactitol was individually adjusted to maintain two semiliquid bowel movements per day. Steatorrhea was determined before and after a minimum of 7 days, when the cathartic effect was stabilized. Treatment with nonabsorbable disaccharides induced mild to moderate steatorrhea in 50% of patients. No differences were observed between the effects of lactulose and lactitol, but fecal fat excretion exceeded 10 g/day in two patients taking lactulose. These findings indicate that treatment with nonabsorbable disaccharides may increase fecal fat excretion in patients with liver cirrhosis. This factor should be taken into consideration when a cirrhotic patient has to take these drugs for a long time.
引用
收藏
页码:125 / 127
页数:3
相关论文
共 50 条
  • [31] HEMOSTASIS ACTIVATION IN PATIENTS WITH LIVER-CIRRHOSIS
    VUKOVICH, T
    TEUFELSBAUER, H
    FRITZER, M
    KREUZER, S
    KNOFLACH, P
    THROMBOSIS RESEARCH, 1995, 77 (03) : 271 - 278
  • [32] PHARMACOKINETICS OF ZIDOVUDINE IN PATIENTS WITH LIVER-CIRRHOSIS
    TABURET, AM
    NAVEAU, S
    ZORZA, G
    COLIN, JN
    DELFRAISSY, JF
    CHAPUT, JC
    SINGLAS, E
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (06) : 731 - 739
  • [33] FLEROXACIN PHARMACOKINETICS IN PATIENTS WITH LIVER-CIRRHOSIS
    BLOUIN, RA
    HAMELIN, BA
    SMITH, DA
    FOSTER, TS
    JOHN, WJ
    WELKER, HA
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (03) : 632 - 638
  • [34] PHARMACOKINETICS OF METOPROLOL IN PATIENTS WITH LIVER-CIRRHOSIS
    JORDO, L
    REGARDH, CG
    ERVIK, M
    LUNDBORG, P
    OLSSON, R
    RONN, O
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1980, 27 (02) : 262 - 262
  • [35] HYPONATREMIA AND REDUCED RENAL PERFUSION DURING DIURETIC ADMINISTRATION IN PATIENTS WITH LIVER-CIRRHOSIS
    BERNARDI, M
    CAPELLI, M
    BUGIARDINI, G
    GASBARRINI, G
    ITALIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1979, 11 (03): : 145 - 145
  • [36] PHARMACOKINETICS OF FAMOTIDINE IN PATIENTS WITH LIVER-CIRRHOSIS
    DUMAS, F
    BALDIT, C
    COUZIGOU, P
    BANNWARTH, B
    VINCON, G
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 1993, 88 (06): : 971 - 972
  • [37] ANALYSIS OF THE SURVIVAL OF LIVER-CIRRHOSIS PATIENTS
    MOCHALOVA, YS
    MUKHIN, AS
    APROSINA, ZG
    SOVETSKAYA MEDITSINA, 1985, (03): : 102 - 107
  • [38] PREVALENCE OF HYPERFIBRINOLYSIS IN PATIENTS WITH LIVER-CIRRHOSIS
    FERRO, D
    QUINTARELLI, C
    SALIOLA, M
    ALESSANDRI, C
    BASILI, S
    BONAVITA, MS
    VIOLI, F
    FIBRINOLYSIS, 1993, 7 (01) : 59 - 62
  • [39] PHARMACOKINETICS OF PHENPROCOUMON IN PATIENTS WITH LIVER-CIRRHOSIS
    KITTERINGHAM, NR
    BUSTGENS, L
    BRUNDERT, E
    MINESHITA, S
    OHNHAUS, EE
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 15 (05) : P590 - P590
  • [40] THE EFFECT OF NITROGLYCERIN ON THE ESOPHAGEAL-VARICES OF PATIENTS WITH LIVER-CIRRHOSIS
    STARITZ, M
    PORALLA, T
    EWE, K
    ZUMBUSCHENFELDE, KHM
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 1984, 22 (09): : 423 - 423